Cargando…
A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy
BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354984/ https://www.ncbi.nlm.nih.gov/pubmed/30703119 http://dx.doi.org/10.1371/journal.pone.0210972 |
_version_ | 1783391282281840640 |
---|---|
author | Pieters, Huibrie C. Green, Emily Khakshooy, Sally Sleven, Miriam Stanton, Annette L. |
author_facet | Pieters, Huibrie C. Green, Emily Khakshooy, Sally Sleven, Miriam Stanton, Annette L. |
author_sort | Pieters, Huibrie C. |
collection | PubMed |
description | BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, interpreted, and acted upon AI-related information. DESIGN: Thematic analysis was used to sort and compare the data into the most salient themes. PARTICIPANTS: Women (N = 54; 27 persisting, 27 not persisting with an AI) aged 65–93 years took part in qualitative interviews. RESULTS: Women in both subgroups described information similarly in terms of its value, volume, type, and source. Aspects of AI-related information that either differed between the subgroups or were misunderstood by one or both subgroups included: (1) knowledge of AI or tamoxifen prior to cancer diagnosis, (2) use of online resources, (3) misconceptions about estrogen, hormone replacement therapies and AI-related symptoms, and (4) risk perception and the meaning and use of recurrence statistics such as Oncotype DX. CONCLUSIONS: Persisters and nonpersisters were similar in their desire for more information about potential side effects and symptom management at AI prescription and subsequent appointments. Differences included how information was obtained and interpreted. Interactive discussion questions are shared that can incorporate these findings into clinical settings. |
format | Online Article Text |
id | pubmed-6354984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63549842019-02-15 A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy Pieters, Huibrie C. Green, Emily Khakshooy, Sally Sleven, Miriam Stanton, Annette L. PLoS One Research Article BACKGROUND: It remains unclear how information about aromatase inhibitors (AI) impacts women’s decision-making about persistence with endocrine therapy. PURPOSE: To describe and compare how women treated for primary early stage breast cancer either persisting or not persisting with an AI received, interpreted, and acted upon AI-related information. DESIGN: Thematic analysis was used to sort and compare the data into the most salient themes. PARTICIPANTS: Women (N = 54; 27 persisting, 27 not persisting with an AI) aged 65–93 years took part in qualitative interviews. RESULTS: Women in both subgroups described information similarly in terms of its value, volume, type, and source. Aspects of AI-related information that either differed between the subgroups or were misunderstood by one or both subgroups included: (1) knowledge of AI or tamoxifen prior to cancer diagnosis, (2) use of online resources, (3) misconceptions about estrogen, hormone replacement therapies and AI-related symptoms, and (4) risk perception and the meaning and use of recurrence statistics such as Oncotype DX. CONCLUSIONS: Persisters and nonpersisters were similar in their desire for more information about potential side effects and symptom management at AI prescription and subsequent appointments. Differences included how information was obtained and interpreted. Interactive discussion questions are shared that can incorporate these findings into clinical settings. Public Library of Science 2019-01-31 /pmc/articles/PMC6354984/ /pubmed/30703119 http://dx.doi.org/10.1371/journal.pone.0210972 Text en © 2019 Pieters et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pieters, Huibrie C. Green, Emily Khakshooy, Sally Sleven, Miriam Stanton, Annette L. A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title | A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title_full | A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title_fullStr | A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title_full_unstemmed | A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title_short | A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
title_sort | qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354984/ https://www.ncbi.nlm.nih.gov/pubmed/30703119 http://dx.doi.org/10.1371/journal.pone.0210972 |
work_keys_str_mv | AT pietershuibriec aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT greenemily aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT khakshooysally aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT slevenmiriam aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT stantonannettel aqualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT pietershuibriec qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT greenemily qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT khakshooysally qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT slevenmiriam qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy AT stantonannettel qualitativecomparisonofhowolderbreastcancersurvivorsprocesstreatmentinformationregardingendocrinetherapy |